Sellas Life Sciences Group, Inc. (SLS) shares are sliding more than 33 percent on Monday morning trade after the company reported third-quarter loss.
The late-stage biopharmaceutical company reported a quarterly net loss of $7.02 million or $0.34 per share compared to $7.085 million or $0.45 per share in the prior year.
There was no licensing revenue for the third quarter of 2022 or 2021.
Currently, shares are at $3.01, down 33.74 percent compared to the prior close of $4.55 on a volume of 705,220. The shares have been on a decline since November 10.
For comments and feedback contact: editorial@rttnews.com
Business News